Champions Oncology (CSBR)
(Delayed Data from NSDQ)
$5.02 USD
-0.04 (-0.79%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $5.10 +0.08 (1.59%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CSBR 5.02 -0.04(-0.79%)
Will CSBR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CSBR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CSBR
Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates
CSBR: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates
Implied Volatility Surging for Champions Oncology (CSBR) Stock Options
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates
Other News for CSBR
Craig-Hallum downgrades Champions Oncology to Hold amid challenging environment
Craig-Hallum gets more bearish on Champions Oncology, downgrades shares
Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript
Earnings Scheduled For March 12, 2024
Champions Oncology Non-GAAP EPS of -$0.16, revenue of $12M